Home > Pulmonology > ERS 2018 > Current look on asthma > Late-breaking Biologics

Late-breaking Biologics

Conference
ERS 2018
Trial
Phase 3, COSMOS, SIROCCO, CALIMA, BORA

During the ERS 2018, long-term safety and efficacy data were presented from 2 ‘post-phase 3’ extension studies with approved anti-IL-5 biologics. The first study, COSMEX, evaluated the long-term safety and effectiveness of mepolizumab in an open label extension of the previous phase 3 COSMOS trials [1]. In this study, 339 patients with very severe, life-threatening, eosinophilic asthma received mepolizumab (100 mg every 4 weeks) for additionally up to 172 weeks. Overall, 93% of patients reported on-treatment adverse events (AEs), which occurred with a frequency of >10%, similar to the previous shorter-term placebo-controlled trials. The frequency of serious AEs was low. Effectiveness of mepolizumab treatment was sustained with substantial reductions in exacerbation rates and oral corticosteroids use, for up to 4.5 years.

The second study, BORA, reported on the long-term safety and effectiveness of benralizumab during an extension of the previous phase 3 trials SIROCCO a...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on